Detalles de la búsqueda
1.
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Int J Mol Sci
; 20(22)2019 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31752127
2.
Serine is a natural ligand and allosteric activator of pyruvate kinase M2.
Nature
; 491(7424): 458-462, 2012 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23064226
3.
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease.
Haematologica
; 104(6): e256-e259, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30545928
4.
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Proc Natl Acad Sci U S A
; 107(35): 15547-52, 2010 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-20713702
5.
Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential in vivo.
Mol Ther Nucleic Acids
; 34: 102055, 2023 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37928443
6.
Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model.
Neuropharmacology
; 162: 107817, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31654704
7.
Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD.
Neuropharmacology
; 162: 107812, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31622602
8.
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Neuropharmacology
; 180: 108297, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32890589
9.
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.
J Med Chem
; 63(22): 13595-13617, 2020 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33166139
10.
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
ACS Med Chem Lett
; 10(10): 1473-1479, 2019 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31620236
11.
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
J Med Chem
; 62(18): 8609-8630, 2019 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31465220
12.
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
Cancers (Basel)
; 11(6)2019 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31167506
13.
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
J Med Chem
; 62(13): 6241-6261, 2019 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31244112
14.
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists.
Bioorg Med Chem Lett
; 18(1): 223-7, 2008 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18006312
15.
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Neuropharmacology
; 140: 107-120, 2018 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30081001
16.
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
J Med Chem
; 61(22): 10084-10105, 2018 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30359003
17.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Clin Cancer Res
; 24(1): 120-129, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066507
18.
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
J Med Chem
; 60(17): 7524-7538, 2017 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28829592
19.
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.
Cell Cycle
; 10(21): 3731-9, 2011 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22045127
20.
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
J Med Chem
; 52(9): 2762-75, 2009 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19419204